eXoZymes Inc. Common Stock EXOZ Business Segments
| Q1 '26 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | ||
|---|---|---|---|---|---|---|
| Cumulative Net Sales by Product | ||||||
| Licensed Product | $1M0.0% | $1M+300% | $250K— | $250K— | $250K— | |
| Second Licensed Product | $2M0.0% | $2M+300% | $500K— | $500K— | $500K— | |
| Payments To Acquire Licensed Product by Product | ||||||
| Licensed Product | $250K0.0% | $250K+300% | $62.5K— | $62.5K— | $62.5K— | |
| Second Licensed Product | $350K0.0% | $350K+300% | $87.5K— | $87.5K— | $87.5K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does eXoZymes Inc. Common Stock break its business down?
- eXoZymes Inc. Common Stock (EXOZ) reports cumulative net sales by product across 2 parts — Licensed Product and Second Licensed Product. Each is extracted from the segment footnotes and tracked over time.
- Where does eXoZymes Inc. Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in eXoZymes Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
